Published in Am Fam Physician on February 01, 1973
5-Fluorocytosine in human cryptococcosis. Antimicrob Agents Chemother (Bethesda) (1968) 3.08
Progressive disseminated histoplasmosis. A prospective study of 26 patients. Ann Intern Med (1972) 1.99
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis (1975) 1.88
Aspergillus species endocarditis. The new face of a not so rare disease. Am J Med (1974) 1.74
In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine. Antimicrob Agents Chemother (Bethesda) (1968) 1.62
North American blastomycosis: a study of 40 patients. Medicine (Baltimore) (1968) 1.56
Chemotherapeutic agents for the pulmonary mycoses. Report of the Committee on Fungus Diseases and Subcommittee on Therapy, American College of Chest Physicians. Chest (1971) 1.53
Preliminary studies on a hyphaforming mutant of Cryptococcus neoformans. Mycologia (1966) 1.46
Thoracic cross-sectional imaging of amyloidosis. AJR Am J Roentgenol (1997) 1.35
Meningoencephalitis due to pathogenic free-living amoebae. Report of two cases. JAMA (1968) 1.30
Intraventricular administration of amphotericin B. Use of subcutaneous reservoir in four patients with mycotic meningitis. JAMA (1965) 1.28
5-fluorocytosine in human candidiasis. Antimicrob Agents Chemother (Bethesda) (1970) 1.22
Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest (2001) 1.20
Cryptococcosis complicating sarcoidosis. Am Rev Respir Dis (1973) 1.12
Epidemic of pulmonary blastomycosis (Namekagon fever) in Wisconsin canoeists. Chest (1984) 1.12
Clinical features of extracutaneous sporotrichosis. Medicine (Baltimore) (1967) 1.08
Flucytosine. N Engl J Med (1972) 1.04
Therapeutic bronchoscopy in broncholithiasis. Am J Respir Crit Care Med (1999) 1.04
Risk of osteoporotic fractures in women with breast cancer: a population-based cohort study. J Chronic Dis (1987) 0.99
Clinical and laboratory studies of a new micronized preparation of hamycin in systemic mycoses in man. Antimicrob Agents Chemother (Bethesda) (1967) 0.99
Meningoencephalitis due to hyphae-forming Cryptococcus neoformans. Am J Clin Pathol (1971) 0.99
External-beam radiation therapy in the treatment of diffuse tracheobronchial amyloidosis. Mayo Clin Proc (2001) 0.99
Sarcoidosis presenting as a central nervous system mass lesion. Chest (1997) 0.97
Cavitary pulmonary infarct in immunocompromised hosts. Mayo Clin Proc (1995) 0.97
Brain abscess caused by Cladosporium trichoides. Arch Intern Med (1976) 0.97
Pulmonary hypertension in patients with amyloidosis. Chest (2001) 0.97
Cardiac echinococcosis: case report of unusual echocardiographic appearance. Mayo Clin Proc (1995) 0.91
Chemotherapy for the systemic mycoses: the prelude to ketoconazole. Rev Infect Dis (1981) 0.90
New drugs for the systemic mycoses: flucytosine and clotrimazole. Bull N Y Acad Med (1975) 0.89
Hamycin: chemotherapeutic studies in systemic mycoses of man. Am Rev Respir Dis (1967) 0.88
Viruria in man, an update. Prog Med Virol (1974) 0.88
Chemotherapy of the systemic mycoses. Med Clin North Am (1982) 0.88
In vitro and in vivo activity of hamycin against Blastomyces dermatitidis. J Bacteriol (1969) 0.86
Candida meningitis. Arch Intern Med (1966) 0.85
Cryptococcus neoformans osteomyelitis: case report of two patients. Sabouraudia (1974) 0.83
Cryptococcal pyelonephritis. N Engl J Med (1968) 0.82
The current status of chemotherapeutic agents for the systemic mycoses. Contrib Microbiol Immunol (1977) 0.81
Pulmonary infection due to opportunistic fungi. Adv Intern Med (1970) 0.79
Pediatric tracheobronchial foreign bodies. A case report. Minn Med (1993) 0.78
Histoplasma and cryptococcus meningitis. Res Publ Assoc Res Nerv Ment Dis (1968) 0.76
Fungal infections of the central nervous system. Clin Neurosurg (1966) 0.76
Troubles in sporotrichosis. N Engl J Med (1969) 0.75
Cryptococcus neoformans and cryptococcosis. Trans Am Clin Climatol Assoc (1970) 0.75
In Vivo Susceptibility of Cryptococcus neoformans to Hamycin, Amphotericin B, and 5-Fluorocytosine. Infect Immun (1970) 0.75
Round table on antifungal agents. Antimicrob Agents Chemother (Bethesda) (1965) 0.75
Fungal infections. Clin Pharmacol Ther (1974) 0.75
55-year-old man with a lung lesion and hemidysesthesia. Mayo Clin Proc (1999) 0.75
Factors predisposing to illness. Mod Treat (1970) 0.75
The polypeptide antifungal agent (X-5079C): further studies in 39 patients. Am Rev Respir Dis (1966) 0.75
Assay of antifungal agent saramycetin (X-5079C) in patient body fluids. Am Rev Respir Dis (1969) 0.75
Indications for chemotherapy in the pulmonary mycoses. A report of the Committee on Fungus Diseases, Subcommittee on Therapy, American College of Chest Physicians. Dis Chest (1969) 0.75
Hamycin toxicity in the dog. Antimicrob Agents Chemother (Bethesda) (1965) 0.75
Antimicrobial therapy in systemic fungal infections. Am J Med (1965) 0.75
To dig I am not able. N Engl J Med (1972) 0.75
Current and future chemotherapy of central nervous system fungal infections. Adv Neurol (1974) 0.75
50-year-old man with fever and rhinorrhea. Mayo Clin Proc (1995) 0.75
Pulmonary lymphoproliferative disorders. Mayo Clin Proc (1993) 0.75
Sarah Elizabeth Stewart. Cancer Res (1977) 0.75
Reducing amphotericin B reactions. 3. Use of a preparation with increased phosphate buffer. Am Rev Respir Dis (1965) 0.75
Recognition and current management of the systemic mycoses. Med Clin North Am (1967) 0.75